Bio-Rad Laboratories, a global provider of life science research and clinical diagnostics products, has expanded its molecular portfolio offering of quality controls with the launch of two new Exact Diagnostics products: synthetic negative run control, which complements the tick-borne, meningitis/encephalitis and sexually transmitted infections products; and hospital-associated infections (HAI) negative run control, which complements the hospital-associated infections products. Both are external quality controls designed to be used with molecular assays to monitor their intra- and inter-run performance. These products may also be used for dilution or spike-in purposes such as assay validation and verification.

Exact Diagnostics HAI Negative Run Control is available from Bio-Rad Laboratories. Photo: Bio-Rad Laboratories

The two new products in the molecular portfolio are the Exact Diagnostics. Synthetic Negative Run Control and the Exact Diagnostics HAI Negative Run Control. The Exact Diagnostics Synthetic Negative Run Control is  screened negative for 9 targets: Anaplasma phagocytophilumBabesia microtiBartonella quintanaBorrelia burgdorferiEhrlichia chaffeensis, Enterovirus (EV) Coxsackievirus A9, Herpes Simplex Virus-1 (HSV-1), Herpes Simplex Virus-2 (HSV-2), and Varicella Zoster Virus (VZV).The Exact Diagnostics HAI Negative Run Control is screened negative for 3 targets: Clostridium (Clostridioides) difficile, Methicillin-resistant Staphylococcus aureus (MRSA), and Methicillin-susceptible Staphylococcus aureus (MSSA).

These products enable laboratories to capture run-to-run, day-to-day, instrument-to-instrument, operator-to-operator, and lot-to-lot variations of the assays the the molecular portfolio . They can also be used to train laboratory operators and evaluate proficiency. Another application is the spike-in and dilution of positive specimens or analyte-containing materials for assay validation and verification.

Both products are designed to save laboratories the time and costs associated with the labor-intensive screening, qualification, manufacturing and maintenance of clinical specimens that would otherwise be used as controls.Both these new products are available now. Visit to learn more about the Exact Diagnostics molecular portfolio.